Boundless Bio, Common Stock Price To Earnings To Growth
| BOLD Stock | USD 2.59 0.07 2.78% |
Boundless Bio, Common fundamentals help investors to digest information that contributes to Boundless Bio,'s financial success or failures. It also enables traders to predict the movement of Boundless Stock. The fundamental analysis module provides a way to measure Boundless Bio,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Boundless Bio, stock.
Boundless | Price To Earnings To Growth |
Boundless Bio, Common Company Price To Earnings To Growth Analysis
Boundless Bio,'s PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Boundless Bio, Price To Earnings To Growth | (1.09) X |
Most of Boundless Bio,'s fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Boundless Bio, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Boundless Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Boundless Bio, is extremely important. It helps to project a fair market value of Boundless Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Boundless Bio,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Boundless Bio,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Boundless Bio,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Boundless Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Boundless Bio, Common has a Price To Earnings To Growth of -1.09 times. This is 253.52% lower than that of the Biotechnology sector and 134.71% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 122.29% higher than that of the company.
Boundless Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Boundless Bio,'s direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Boundless Bio, could also be used in its relative valuation, which is a method of valuing Boundless Bio, by comparing valuation metrics of similar companies.Boundless Bio, is currently under evaluation in price to earnings to growth category among its peers.
Boundless Bio, Current Valuation Drivers
We derive many important indicators used in calculating different scores of Boundless Bio, from analyzing Boundless Bio,'s financial statements. These drivers represent accounts that assess Boundless Bio,'s ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Boundless Bio,'s important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.4B | 938.7M | 1.3B | 222.39 | 255.75 | 242.96 | |
| Enterprise Value | 1.3B | 801.4M | 1.3B | (5.8M) | (21.5M) | (20.4M) |
Boundless Bio, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Boundless Bio,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Boundless Bio,'s managers, analysts, and investors.Environmental | Governance | Social |
Boundless Fundamentals
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | (98.56 M) | ||||
| Shares Outstanding | 22.25 M | ||||
| Shares Owned By Insiders | 11.46 % | ||||
| Shares Owned By Institutions | 78.60 % | ||||
| Number Of Shares Shorted | 180.74 K | ||||
| Price To Earning | (7.22) X | ||||
| Price To Book | 0.45 X | ||||
| EBITDA | (48.48 M) | ||||
| Net Income | (49.43 M) | ||||
| Cash And Equivalents | 351.46 M | ||||
| Cash Per Share | 7.68 X | ||||
| Total Debt | 2.19 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.80 X | ||||
| Book Value Per Share | 8.05 X | ||||
| Cash Flow From Operations | (46.85 M) | ||||
| Short Ratio | 10.24 X | ||||
| Earnings Per Share | (2.59) X | ||||
| Price To Earnings To Growth | (1.09) X | ||||
| Target Price | 18.33 | ||||
| Number Of Employees | 72 | ||||
| Beta | 2.19 | ||||
| Market Capitalization | 79.89 M | ||||
| Total Asset | 129.89 M | ||||
| Retained Earnings | (136.11 M) | ||||
| Working Capital | 114.84 M | ||||
| Current Asset | 99.64 M | ||||
| Current Liabilities | 104 K | ||||
| Net Asset | 129.89 M |
About Boundless Bio, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Boundless Bio, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boundless Bio, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boundless Bio, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio, Common is a strong investment it is important to analyze Boundless Bio,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio,'s future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out Boundless Bio, Piotroski F Score and Boundless Bio, Altman Z Score analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.